{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:28:48Z","timestamp":1753892928849,"version":"3.41.2"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"DOI":"10.3389\/fpubh.2022.959678","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T21:51:12Z","timestamp":1658785872000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adapting malaria clinical trials infrastructure to implement COVID-19 epidemiology studies: Response to a public health emergency amid safe continuation of a research enterprise"],"prefix":"10.3389","volume":"10","author":[{"given":"John","family":"Woodford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issaka","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alassane","family":"Dicko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"B1","unstructured":"DuffyPE\n          NCT03917654: Pfs230D1M-EPA\/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium falciparum, in an Age De-Escalation Trial of Children a Family Compound Trial in Mali.2019"},{"volume-title":"NCT03952650. Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac approach): A Randomized Double Blind Placebo Controlled Phase I\/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum Infection in Bancoumana and Surrounding Areas, Mali","year":"2019","author":"Duffy","key":"B2"},{"volume-title":"NCT03989102: Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali","year":"2019","author":"Duffy","key":"B3"},{"key":"B4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12961-020-00623-8","article-title":"Coordinating the research response to COVID-19: Mali's approach","volume":"18","author":"Doumbia","year":"2020","journal-title":"Health Res Policy Syst."},{"key":"B5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41467-020-20383-x","article-title":"Standardization of ELISA protocols for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling","volume":"12","author":"Klumpp-Thomas","year":"2021","journal-title":"Nat Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1093\/infdis\/jiab498","article-title":"SARS-CoV-2 seroassay performance and optimization in a population with high background reactivity in Mali","volume":"224","author":"Woodford","year":"2021","journal-title":"J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"781586","DOI":"10.3389\/fitd.2021.781586","article-title":"Assessing and minimizing the effect of malaria on SARS-CoV-2 serodiagnostics","volume":"2","author":"Woodford","year":"2021","journal-title":"Front Trop Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1093\/cid\/ciab589","article-title":"Rapidly increasing SARS-CoV-2 seroprevalence and limited clinical disease in three Malian communities: a prospective cohort study","volume":"74","author":"Sagara","year":"2021","journal-title":"Clin Infect Dis."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.959678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T21:51:16Z","timestamp":1658785876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.959678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":8,"alternative-id":["10.3389\/fpubh.2022.959678"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.959678","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,7,26]]},"article-number":"959678"}}